Alexion's star Soliris wins NICE backing; Ranbaxy slumps to quarterly loss; Novo undeterred in Russia;

@FiercePharma: #Pfizer extricates itself from investor lawsuit with $400M payment. More | Follow @FiercePharma

@EricPFierce: Pfizer settles investor suit over marketing probe of Bexta for $400M. Story | Follow @EricPFierce

> The U.K.'s cost-effectiveness watchdogs gave their final blessing to Alexion's ($ALXN) rare disease drug Soliris (eculizumab), which is, at £340,200 per year, the most expensive drug ever approved by the agency. Report

> India's Ranbaxy Laboratories, soon to be sold to Sun Pharmaceuticals, swung back to a loss for the most recent quarter as sales waned and a one-time tax payment ate into earnings. Report

> Novo Nordisk ($NVO) says it's not deterred from investing in the Russian pharma market despite the country's economic turndown and conflict in the Ukraine. Report

> Novartis ($NVS) is in talks to sell a former research site in Horsham, England, to the University of Brighton. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: AdvaMed: China's push for hospitals to buy domestic devices all talk, no action. Article | Follow @FierceMedDev

@EmilyWFierce: Find out which med tech companies scored key device approvals in 2014 in @FierceMedDev's latest special report. Feature | Follow @EmilyWFierce

> St. Jude gains FlexAbility approval, lays out 2015 sales growth strategy. Article

> Illumina soars 32% in Q4 with sales of next-gen sequencing system. News

Biotech News

@FierceBiotech: Pfizer's hunting for safe M&A bets, not high-risk pipeline deals. Article | Follow @FierceBiotech

@JohnCFierce: $GSK and $NVS get EU clearance for the Big Swap -- selling some assets along the way. More | Follow @JohnCFierce

@DamianFierce: News to me: $AMGN's PCSK9 blocker will sell as Repatha, which sounds a bit like a mid-sized sports utility vehicle. | Follow @DamianFierce

> Interested in biotech financing in the U.K.? Story

> Wells Fargo dispatches biotech banker to Cambridge/Boston supercluster. News

Drug Delivery News

> PARI snags FDA approval for cystic fibrosis nebulizer platform. News

> Microneedle patch maker Zosano Pharma raises $50M in IPO. Article

> Nanomed lifetime is an important aspect of delivery potential, scientists say. More

> Shire's intrathecally delivered candidate for Hunter syndrome gets FDA's Fast Track Designation. Report

> Australian team developing novel formulation to deliver common diabetes drug. Article

Diagnostics News

> Myriad settles patent feud with Invitae, Pathway Genomics over BRCA technology. News

> Roche nabs FDA OK for drug-resistant bacteria test. More

> Sequenom strikes a deal with Cypher Genomics to develop advanced noninvasive prenatal test. Report

> Sera Prognostics taps industry niche with preterm birth risk test. Story

> Roche's Ventana inches closer to FDA approval for lung cancer companion Dx. Article

Pharma Marketing News

> Novartis revs up Cosentyx launch as it braces for a psoriasis pricing war. News

> Express Scripts takes a bow for cutting $4B off hep C drug spending. Article

> Auryxia differentiation strategy, check. Next, Keryx has to persuade prescribers. Story

> Bayer, J&J launch new stroke study to pump up payer-persuading Xarelto data. More

> Valeant bets big on the Super Bowl with $4.5M toe-fungus ad. Article

> And Finally... Actavis ($ACT) CEO Brent Saunders talked M&A, including its latest deal for generics maker Auden Mckenzie, with Maria Bartiromo on Fox Business. Video

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.